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PURPOSE. Proliferative vitreoretinopathy (PVR) is still the major
cause of failure of retinal detachment (RD) surgery and
although the risk for developing this complication is associated
with some clinical characteristics, the correlation is far from
absolute, raising the possibility of genetic susceptibility. The
objective of this study was to analyze the genetic contribution
to PVR in patients undergoing RD surgery, the Retina 4 Project.
METHODS. A candidate gene association study was conducted in
2006 in a Spanish population of 450 patients suffering from
primary rhegmatogenous RD. Replication was carried out in a
larger population undergoing RD surgery at several European
centers among 546 new patients. Single nucleotide polymor-
phism (SNP) of 30 genes known to be involved with
inflammation were analyzed. For replication stage, those genes
previously detected as significantly associated with PVR were
genotyped. Distribution of allelic and haplotypic frequencies in
case and control group were analyzed. Single and haplotypic
analysis were assessed. The Rosenberg two-stage method was
used to correct for single and multiple analyses.
RESULTS. After correction for multiple comparisons, four genes
were significantly associated with PVR: SMAD7 (P ¼ 0.004),
PIK3CG (P¼ 0.009), TNF locus (P¼ 0.0005), and TNFR2 (P¼
0.019) In the European sample, replication was observed in
SMAD7 (P ¼ 0.047) and the TNF locus (P ¼ 0.044).
CONCLUSIONS. These results confirm the genetic contribution to
PVR and the implication of SMAD7 and TNF locus in the
development of PVR. This finding may have implications for
understanding the mechanisms of PVR and could provide a
potential new therapeutic target for PVR prophylaxis. (Invest
Ophthalmol Vis Sci. 2013;54:1665–1678) DOI:10.1167/
iovs.12-10931
Proliferative vitreoretinopathy (PVR) is still in this era themajor cause of failure of retinal detachment (RD) surgery
with an incidence of 5% to 10%.1 It is believed to represent an
abnormal wound healing process induced by a retinal break,
which allows egress of RPE cells into the vitreous cavity and
there is strong evidence that inflammation plays an important
role.2,3 Following RD, the blood–ocular barrier breaks down,
possibly due to disruption of the photoreceptor-RPE cell
interface, and inflammatory cells are recruited together and
increase in inflammatory mediators.4–6 Growth factors and
cytokines present in the vitreous cavity may be responsible for
cell migration, metaplasia, and proliferation,7–9 which can
result in the development of glial scar tissue and retinal
contraction.10–13
Most researches in this field have orientated their efforts to
identify clinical factors responsible of this pathologic repairing
process (such as, the method of retinopexy or tamponade
used). However, it seems likely as a cell-based inflammatory
response that genetic susceptibility may have a role, particu-
larly as PVR can occur in patients with prompt and initially
successful surgery following a primary rhegmatogenous
RD.14,15 Hence, we are still unable to predict the risk of PVR
reliably and apart from surgery, there is currently no
prevention or cure.16–18
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We have learned that many diseases are the consequence of
interaction between environmental factors (clinical variables)
and the genetic profile of each subject.19,20 Considering this
concept of complex disease, we decided to investigate the
genetic component of PVR. One preliminary study conducted
by our group in a small sample had showed in 2005 an
association between the TGF-b1 and PVR.21 We also developed
three predictive models of PVR based on the analysis of genetic
variables.22
The Retina 4 project, a candidate gene and replication study
strategy, overcomes one of the major problems with associa-
tion studies in generating false positives.23,24 Associations need
to be replicated in order to confirm their veracity. For that
reason, this study comprises two stages: the discovery stage,
where only samples coming from Spanish centers were
analyzed; and the replication stage, where new samples
coming from centers in Spain, Portugal, the Netherlands, and
the United Kingdom were studied.
METHODS
Setting and Design
A case-controlled, candidate gene association study was conducted in
2006 among patients from eight centers in Spain, the discovery stage
(Table 1). For the replication stage, a European multicenter case-
controlled association study in those genes found significantly
associated to PVR in the discovery stage (TNF locus, mothers against
decapentaplegic (SMAD7), phosphatidyl inositol 3-kinase, catalytic,
gamma (PIK3CG), and TNFR2) was conducted between 2009 and
2010. All patients provided written informed consent, and the study
was approved by the institutional research committees of each center
and followed the tenets of the Declaration of Helsinki.
Study Population
Both samples were composed of patients who had undergone
primary rhegmatogenous RD surgery. Careful ophthalmoscope
examination by slit lamp and indirect ophthalmoscope were
performed postoperatively to classify the patient as case or control.
Those who developed PVR grade C1 or higher25 after surgery were
included as a case. Those who did not develop PVR after 3 months of
follow up were included in the control group. To achieve a stringent
phenotype classification, other causes than a primary rhegmatogenous
RD, such as traumatic, tractional, exudative, or iatrogenic RD were
excluded. Exclusion criteria were also RD secondary to macular hole,
giant retinal tears defined by more than 3 hours, patients with
preoperative PVR grade C1 or higher,25 and patients with RD in the
affected eye and RD with PVR in the fellow eye. In addition, clinical
characteristics that could affect the stringent phenotypification were
investigated like race, family history of RD, status of the lens, and so on
(Table 2). Surgeon experience was also valorated. Experts were
considered to be those who had already performed greater than or
equal to 100 pars plana vitrectomy (PPV) and no experts those with
less than 100 PPV.
In the discovery stage only patients coming from Spanish centers
were included, while in the replication stage participants were
completely new patients coming from centers in Holland, Portugal,
Spain, and the United Kingdom (Table 1). Inclusion of patients during
the replication stage coming from centers that participated in the
former stage was consecutive and prospective. Simulation-based power
analysis by bootstrap was used for sample size determination of
replication stage.
Measures
Blood Collection and DNA Extraction. A peripheral blood
sample was used for DNA extraction, which was performed using the
commercial REALpure Kit protocol SSS (DURVIZ SL, Valencia, Spain),
or similar. Genotyping was performed by the Genotyping Center
(CeGen-ISCIII, Santiago de Compostela, Spain). For the discovery stage,
the SNPlex Genotyping System (Applied Biosystem, Foster City, CA)
was used. For the replication sample the MassARRAY SNP Genotyping
System (Sequenom Inc., San Diego, CA) was used following the
manufacturer’s instructions. The principles of this method are detailed
in Buetow et al.26
Genes and Single Nucleotide Polymorphism Selection.
According the inflammatory nature of PVR,2,27 the following 30
candidate genes were investigated in the discovery stage: connective
tissue growth factor (CTGF), epidermal growth factor (EGF), fibroblast
growth factor (FGF), hepatocyte growth factor (HGF), insulin-like
growth factor 1 (IGF-1), interferon gamma (IFNG), insulin-like growth
factor 2 (IGF-2), insulin-like growth factor I receptor (IGF1R),
interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), interleukin 1
receptor antagonist (IL1RN), interleukin 6 (IL6), interleukin 8 (IL8),
interleukin 10 (IL10), monocyte chemotactic protein 1 (MCP1),
macrophage migration inhibitory factor (MIF), matrix metalloprotei-
nase (MMP)-2, matrix metalloproteinase 7 (MMP7), nuclear factor
kappa-b subunit 1 (NFKB1), nuclear factor of kappa light chain gene
enhacer in B cells inhibitor alpha (NFKBIA), nuclear factor of kappa
light chain gene enhacer in B cells inhibitor beta (NFKBIB), platelet-
derived growth factor (PDGF), platelet-derived growth factor receptor
alpha (PDGFRa), PI3K, SMAD3, SMAD7, transforming growth fator
beta 1 (TGF-b1), transforming growth fatcor beta 2 (TGF-b2), tumor
necrosis factor alpha (TNF-a), and tumor necrosis factor receptor 2
(TNFR2). Common tag SNPs with correlation coefficients greater than
or equal to 0.85 and a minor allelic frequency greater than or equal to
10% were studied to explain as much as possible the known genetic
variation for each gene. The Tagger method implemented in the
Haploview program (provided in the public domain by Broad Institute;
http://www.broad.mit.edu/mpg/haploview/) was used for this pur-
pose.28 According to the linkage disequilibrium observed in the TNF-a
region, the following four genes were necessary to be investigated in
the TNF locus: lymphotoxin alpha (LTa), TNF-a, leucocyte specific
transcript 1 (LST1), and the activating natural killer receptor p30
(NCR3). Genic and extragenic regions 10 kb upstream and downstream
were considered for each gene. Functional SNPs or ones previously
described in association with other inflammatory diseases were added
for analysis.29–33 In the replication stage same SNPs previously studied
in PIK3CG, SMAD7, TNF locus, and TNFR2 (30 SNPs) were
investigated.
Statistical Analysis
Preliminary and Descriptive Analysis. The data quality were
evaluated by Hardy-Weinberg equilibrium using a Pearson goodness-of-
fit test. When there was a low genotype count, a Fisher exact test was
used. Data quality were also evaluated by differential missingness
between cases and controls. Allelic and genotypic frequencies were
estimated.
Test of Association: Single SNPs. Single associations were
established using the v2 and Fisher tests. Five inheritance models
were defined: (1) In the codominant model, every genotype gave a
different and nonadditive risk, (2) in the dominant model, a single copy
of the variant allele was enough to modify the risk, (3) in the recessive
model, two copies of the variant allele were necessary to change the
risk, (4) in the over dominant model, heterozygosity was compared
with a pool of each allele homozygosity, and (5) in the additive model,
each copy of the variant allele modified the risk in an additive form.
The Akaike Information Criteria (AIC) was used to choose the
inheritance model that best fit the data.
Test of Association: Haplotypic SNPs. Haplotypes consistent
with the sample were analyzed taking into consideration blocks from
as few as two consecutive markers (subhaplotypes) to as much as all of
the markers included in each gene (haplotypes). Haplotypic frequen-
cies were estimated using the expectation-maximization algorithm.34
To evaluate the association between haplotypes and disease, general-
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ized linear models were used. The effects of haplotypes were modeled
as additive, dominant, and recessive. The log-likelihood criterion was
used to select the best model.
Multiple Testing and False Discovery Rate Analysis. To correct
for multiple analyses, the Rosenberg two-stage method was used.35 For
the first stage, single-SNP association tests and haplotype-SNP
association tests within one gene were considered. An omnibus test
that combined SNP and haplotype analysis was then constructed. This




where pSNP was the Simes-adjusted P value36 for the most significant
SNP, and pHAP was the Simes-adjusted P value for the most significant
haplotype. The distribution of the omnibus test statistic under the
independence hypothesis was computed from the permutation
distribution obtained by shuffling case and control indicators. In the
second stage, summary gene P values were adjusted for multiplicity by
controlling the expected false discovery rate with the Benjamini-
Hochberg procedure (q-value).37
All statistical analyses were conducted using R software including
SNPassoc and haplo.stat packages.38–40
RESULTS
Discovery Stage
Four hundred fifty patients were analyzed, including 138 cases
and 312 controls. A total of 230 SNPs distributed along the 30
TABLE 1. Centers Involved in the Study
Country Center
Discovery Stage Replication Stage
Cases PVR Controls RD Total Cases PVR Controls RD Total
England
Moorfields Eye Hospital, London N - - - 32 118 150
% Total - - - 5.9 21.6 27.5
Holland
Rotterdam Eye Hospital, Rotterdam N - - - 39 89 128
% Total - - - 7.1 16.3 23.4
Portugal
Coimbra University Hospital, Coimbra N - - - 6 1 7
% Total - - - 1.1 0.2 1.3
Sao Joao Hospital, Oporto N - - - 6 52 58
% Total - - - 1.1 9.5 10.6
Spain
Germans Trias i Pujol University Hospital, N - - - 11 11 22
Badalona % Total - - - 2.0 2.0 4.0
Jiménez D́ıaz Foundation, Madrid N - - - 2 2 4
% Total - - - 0.4 0.4 0.7
Ophthalmological Foundation of Mediterranean, N - - 5 2 7
Valencia % Total - - 0.9 0.4 1.3
San Millan San Pedro Hospital, Logroño N - - - 9 1 10
% Total - - - 1.6 0.2 1.8
Universitary Hospital La Fe, Valencia N - - - 10 25 35
% Total - - - 1.8 4.6 6.4
University Hospital of Navarra N - - - 11 19 30
% Total - - - 2.0 3.5 5.5
Universitay Hospital Ramón y Cajal, Madrid N - - - 2 3 5
% Total - - - 0.4 0.5 0.9
Barraquer Ophthalmology Centre N 8 35 43 2 6 8
% Total 1.8 7.8 9.5 0.4 1.1 1.5
Donostia Hospital, San Sebastian N 7 35 42 2 0 2
% Total 1.5 7.8 9.3 0.4 0 0.4
IOBA (University Eye Institute), Valladolid N 28 22 50 10 15 25
% Total 6.2 4.9 11.1 1.8 2.7 4.6
Reina Sofia Universitary Hospital, Cordoba N 5 9 14 - - -
% Total 1.1 2 3.1 - - -
Universitary Hospital Pio del Rio Hortega N 7 10 17 - - -
% Total 1.5 2.2 3.8 - - -
University Hospital Vall d’Hebrón N 20 75 95 1 25 26
% Total 4.4 16.7 21.1 0.2 4.6 4.8
University Hospital of Valladolid N 32 28 60 2 8 10
% Total 7.1 6.2 13.3 0.4 1.5 1.8
Vissum, Alicante N 31 98 129 1 18 19
% Total 6.9 21.8 28.7 0.2 3.3 3.5
TOTAL N 138 312 450 151 395 546
% Center 30.7 69.3 100.0 27.7 72.3 100.0
N, number of patients from each center; % Center, distribution of patients coming from each center in percent; % Type, distribution of case
control for each center in percent; % Total, percentage of patients from each center to the total amount of patients included.
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Total P ValueN % Type N % Type
Sex
Male 100 28.74 248 71.26 348 0.362
Female 45 25.00 135 75.00 180
Total 145 (6)8 27.46 383 (12)8 72.54 528
Race
North-African 0 0 6 100 6 0.0644
Asian 2 40.00 3 60.00 5
European 133 26.44 370 73.56 503
Hispanic 7 53.85 6 46.15 13
Indian 5 41.67 7 58.33 12
Subsaharian 2 50.00 2 50.00 4
Total 149 (2)8 27.44 394 (1)8 72.56 543
RD family history
No 142 27.52 374 72.48 516 0.932
Yes 9 30 21 70 30
Total 151 27.66 395 72.34 546
PVR family history
No 149 27.49 393 72.51 542 0.4758*
Yes 1 50 1 50 2
Total 150 (1)8 27.57 394 (1)8 72.43 544
RD in fellow eye
Unknown 5 38.46 8 61.54 13 0.5289*
No 136 27.7 355 72.3 491
Yes 10 23.81 32 76.19 42
Total 151 27.66 395 72.34 546
PVR in fellow eye
Unknown 5 38.46 8 61.54 13 0.0057*
No 141 26.70 387 73.30 528
Yes 5 100 0 0 5
Total 151 27.66 395 72.34 546
Phakia/aphakia
Unknown 7 33.33 14 66.67 21 0.2333
Aphakia 19 38.78 30 61.22 49
Pseudophakia 40 28.37 101 71.63 141
Phakia 85 25.37 250 74.63 335
Total 151 27.66 395 72.34 546
Retinopexy
No 147 27.63 385 72.37 532 0.8268*
Yes 4 28.57 10 71.43 14
Total 151 27.66 395 72.34 546
Scleral surgery (SS)
No 116 25.55 338 74.45 454 0.0281*
Yes 34 38.2 55 61.8 89
Total 150 (1)8 27.62 393 (2)8 72.38 543
SS þ drainage
No 131 29.18 318 70.82 449 0.0383*
Yes 20 20.62 77 79.38 97
Total 151 27.66 395 72.34 546
PPV
No 15 10.87 123 89.13 138 <0.0001
Yes 136 33.33 272 66.67 408
Total 151 27.66 395 72.34 546
Air
No 138 26.59 381 73.41 519 0.0153*
Yes 13 48.15 14 51.85 27
Total 151 27.66 395 72.34 546
SF6
No 87 30.21 201 69.79 288 0.0077*
Yes 64 24.81 194 75.19 258
Total 151 27.66 395 72.34 546
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candidate genes were investigated. Six SNPs did not pass the
design pipeline, and 27 failed during the genotyping process.
All informative SNPs verified the Hardy-Weinberg equilibrium
except one. It was located in the PDGFa gene and was
eliminated because it exhibited poor performance during the
genotyping process. Thus, a total of 196 SNPs were analyzed,
yielding a conversion rate of 85.2%.
Single and Haplotypic Associations. Twenty two single
significant associations were observed in 16 genes: EGF, IGF1,
IL1RN, MIF, MMP-2, NFKB1, NFKBIA, NFKBIB, PDGFA,
PDGFRA, SMAD3, SMAD7, TGFB1, TGFB2, TNF locus, and
TNFR2 (Table 3). Following permutation, only three single
significant associations in three genes were detected: the
rs243845 in MMP-2 (P¼ 0.050), the rs7226855 in SMAD7 (P¼
0.0015), and the rs2229094 in TNF locus (P ¼ 0.0283) (Table
3).
In multiple analyses, significant haplotypic and subhaplo-
typic associations were detected in 13 genes: IGF-IR, IL-10,
IL6, MIF, MMP-2, NFKB1, NFKBIA, NFKBIB, PIK3CG, SMAD3,
TGF-b2, TNF locus, and TNFR2 (Table 4). Following permuta-
tion, five genes maintained their significant association: NFKB1
(P¼ 0.0460), NFKBIA (P¼ 0.0460), PIK3CG (P¼ 0.0010), TNF
locus (P ¼ 0.0050), and TNFR2 (P ¼ 0.0130) (Table 4).
Taking into consideration now the total amount of genes,
following the second stage of the Rosenberg method, four
genes maintained significant association with PVR (Table 5):
PIK3CG (P ¼ 0.009), SMAD7 (P ¼ 0.004), TNF locus (P ¼
0.005), and TNFR2 (P ¼ 0.019).
Replication Stage
A total of 546 peripheral DNA blood samples (151 cases and
395 controls) from 17 European centers were included (Table
1). Seventy-one SNPs were included. There was one failure in
the design of the primers, the one corresponding to the
rs1982073. There were no failures for the genotyping process,
with a global call rate of 97.59%. The genotypic data quality
was evaluated, and all informative markers verified the Hardy-
Weinberg equilibrium.
Regarding clinical information some significant associations
were observed. The control group was significantly older than
cases (P < 0.0001) with a median of 6 years (95% confidence
interval [CI]: 3.39–8.31). Patients with history of PVR in the
fellow eye were more frequently cases (83%) than controls
(17%). Pneumatic retinopexy was more frequently performed
on patients that did not developed PVR (71%); scleral surgery
(P ¼ 0.0281), PPV (P < 0.0001), and tamponade-like air (P ¼
0.0153) or silicone oil (SO) (P < 0.0001) were more frequent
in cases, while scleral surgery plus drainage (SS þ d) (P ¼
0.0383), SF6 as tamponade (P¼ 0.0077), and cryotherapy (P¼
0.0481) were significantly less frequent in cases. Regarding
systemic and ocular diseases and treatment occurring simulta-
neously with the RD, very few patients reported inherited
ocular disease or connective tissue disease (1 case versus 11
controls and 1 case versus 13 controls, respectively). Seven
cases were receiving systemic nonsteroidal anti-inflammatory
drugs (NSAIDs), 2 steroids, and 1 antiproliferant treatment
when suffered from RD versus 21, 6, and 2 controls,
respectively. One case was receiving topic steroids, while 7
controls were receiving ocular NSAIDs, and 15 steroids. In the
same way as in the discovery stage, none of the patients
received intravitreal Triamcinolone Acetonide (TA) in any
surgery. Fifty one percent of patients who suffered from PVR
following a RD surgery were operated on by an experienced
surgeon (nontraining grade). There were no significant
associations with sex, race, affected eye, family history of
PVR, or phakic/aphakic status. There were no differences
regarding the geographical localization or center where the
patients came from.
Single and Haplotypic Associations. In the single
analysis new significant associations were observed in PIK3CG
(rs4460309, P¼ 0.0457), SMAD7 (rs6507877, P¼ 0.0345), and
TNF locus (rs2256974, P ¼ 0.02615; rs909253, P ¼ 0.005917;
rs1799964, P ¼ 0.03152; and rs1800629, P ¼ 0.04563) (Table
3). No associations were observed in TNFR2. One replication
was detected, the rs7226855 in SMAD7 (P¼ 0.0064) (Table 3).
Following permutation, all genes maintained their association:






Total P ValueN % Type N % Type
C3F8
No 116 26.54 321 73.46 437 0.3041*
Yes 35 32.11 74 67.89 109
Total 151 27.66 395 72.34 546
Silicone
No 55 13.03 367 86.97 422 <0.0001*
Yes 96 77.42 28 22.58 124
Total 151 27.66 395 72.34 546
Laser
No 35 13.41 226 86.59 261 <0.0001*
Yes 116 40.7 169 59.3 285
Total 151 27.66 395 72.34 546
Cryotherapy
No 99 31.03 220 68.97 319 0.0481*
Yes 52 22.91 175 77.09 227
Total 151 27.66 395 72.34 546
N, number of patients. (N)8 Missing information is indicated for each variable in parentheses. In bold, statistical significant values.
* v2 or Fisher exact test.
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In multiple analyses, no haplotype was associated to PVR.
One subhaplotype was significantly associated in the SMAD7,
the one which implies the two first markers: rs4939826-
rs7226855 (P ¼ 0.0330; odds ratio [OR] ¼ 1.4062; CI 95%:
1.0637–1.8590). However, this association was lost following
permutation (Table 4).
Finally, after corrections for multiple comparisons, replica-
tion was observed in two genes: SMAD7 (P¼ 0.047) and TNF
locus (P ¼ 0.044) (Table 5).
DISCUSSION
In the present study, we analyzed common genetic variants in
genes implicated in the inflammatory cascade in order to
investigate their role in the susceptibility to developing PVR
following primary rhegmatogenous RD surgery.
After the discovery stage, four genes maintained their
significant association to the disease following a very stringent
statistical analysis. This finding warranted investigation wheth-
er these associations were genuine or not, as is recommended
in the literature.23,24,41,42 In the replication stage, studying a
new larger sample of DNA from patients across different
countries in Europe, two of these four genes continued to be
significant: the SMAD7 and the TNF locus.
Limitations of this work must be discussed before analyzing
our results. Despite the fact that the exact mechanisms
responsible of PVR are not completely understood, it is widely
accepted that inflammation plays an important role in its
pathogenesis.3 Although not every gene participating in the
inflammatory cascade could be included, genes encoding for
the key mediators and their signaling pathway molecules were
investigated. Genetic variation in each gene was widely
covered, taking into consideration that in addition to the
parameters used for the SNPs selection (TagSNPs with a r2 ‡
0.85), previously described as functional SNPs and extragenic
regions were also studied.
Other important issue in an association study is the sample
size.24 When we analyze markers with a very subtle effect on
the entire population, there is a significant risk that the genes
may be below the threshold for detection. The power sample
was greater than 80% for most of genes. In the replication stage
TNFR2 did not reach 70%, as it would have been necessary to
collect more than 800 samples to achieve this power. This
would be extremely challenging for a low prevalence condition
such as PVR. This could have been one of the reasons for not
detecting replication in this gene.
An inadequate phenotyping and stratification are other
factors that could invalidate these kinds of studies.41 In order
to prevent this, very stringent exclusion and inclusion criteria
for classification of patients were defined (e.g., PVR patients
were included only once they have been operated on by PPV,
confirming preoperatively the diagnosis by the membrane
peeling; complexity of RDs was homogeneous as those
patients with PVR grade C1 or higher were excluded).
Although not all clinical variables related with a high risk of
developing PVR were recorded, the classification process
exhaustively covered others that could induce any kind of error
during the phenotyping process and that could also introduce
biases such as history of trauma, status of the lens, and so on.
In addition to phenotyping, location is the other main source
of subpopulation in these kind of studies. No differences
regarding geographical origin or center where the patients
came from were found as well as race, sex, and so on.
Methodology of collection of samples was also carefully
defined for the replication stage in order to avoid including
same patients in those centers that had participated in the
discovery stage.
In the replication stage, there were some differences among
clinical variables that worth to be discussed. Cases were
younger than controls and this could be considered a
confounding factor. However, this difference was only 6 years,
making it unlikely that this is responsible for the differences
found in the genetic profiles of cases and controls. Moreover,
this difference should not be of concern as in another work
carried out by our group we found that in people aged over 55
there was a risk for PVR (Pastor JC, Fernandez I, Rodriguez de
la Rua E, et al., unpublished data, 2012). In younger patients
(who had a higher rate of PVR), the posterior vitreous may be
more frequently attached and is more difficult to peel.
Although the difference in age between groups was not great,
this could explain why non PVR controls are older than cases
in our sample. A history of PVR in the fellow eye was more
frequently observed in cases, as is expected since those
patients with RD and history of PVR in the fellow eye were
excluded. Regarding the systemic or ocular diseases and
treatments receiving at the time of the RD, there were very
few patients that reported these characteristics. Then it would
not be appropriate to draw any conclusion about it. Regarding
the differences observed in the intraoperative variables, it is
important to point out that each procedure was recorded as
positive or negative. In this way, one patient could have been
operated on by more than one procedure (e.g., SSþ d and PPV
in a second time). This justifies that PPV or the usage of SO as
tamponade are more frequent among cases. Cases could have
required intravitreal procedures in order to peel membranes
while scleral procedures could have been sufficient among
controls. These differences could be considered a bias, as they
could mean that we have included more complicated RDs in
the case group, and then we could have an spurious
association. However, there are some issues to emphasize.
First, it is has been demonstrated that current tendency of
retinal surgeons toward PPV for treating RDs is not based in a
judgment of the degree of complexity of the RDs. In addition to
that, if we take into account that PVR is per se a complication
of the RD surgery, we could say that we did analyze more
complicated RD in this group. The question that arises here is
why these RDs are more complicated. Genetic profile could be
one of the answers. In order to avoid this confounding factor,
those procedures orientated to treat the RDs once the patient
developed PVR should have probably been eliminated. In this
way, only procedures in RDs clinically comparable would have
been considered and this intŕıngulis would have been solved.
Despite that, it worth to remark that phenotype was carefully
defined, and well recognized experts on the vitreoretinal
surgery were in charge of classifying the patients. Therefore,
we consider that we can rely that patients were correctly
classified as case or control. Since phenotyping was correctly
performed, we consider that all mentioned above do not
invalidate our work.
It is important to remark that half of patients who suffered
from PVR following RD surgery were operated on by an
experienced surgeon. This allows us to downplay the
influence of the surgeon’s skill in the susceptibility to develop
PVR, stressing also the importance of the genetic component.
Finally, one of the major pitfalls of genetic association studies is
the problem of multiple comparisons, which may throw up
anomalous connections purely by chance.24 In order to limit
the presence of these spurious associations we have used a
multiple comparison procedure based on the estimation of the
false discovery rate (FDR).35 The estimation of this rate of
‘‘false positives’’ was used to correct the original P values. We
have set the threshold of significance level, traditionally 0.05,
and we have considered that a association is statistically
significant when the adjusted P value, and not the original P
value, is less than this threshold.
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Threshold of significance is another important issue here.
Ioannidis states that the threshold for declaring the presence or
not of an effect can still be a subject of discussion of schools of
statistics.43 In our study, we observed P values well below the
traditional 0.05 that Ioannidis admits for the replication data
(0.0070 for SMAD7 and 0.0060 for TNF locus in the single
analysis of replication data). Following the FDR estimation, we
observed that 95% of these associations can be genuine, which
can be consider a reliable result to continue working on these
genes in future researches.
Regarding the replication found in SMAD7 gene and the
TNF locus, it reinforces the idea that prevention or even
treatment of PVR should probably be targeted to the
inflammation mediators and their signaling pathway mole-
cules.
High vitreous levels of TNF-a and its receptors (TNFR1 and
2) have been found in eyes with PVR44 and local production of
TNF-a has been suggested to occur in these eyes.45 Keeping in
mind the important role of TNF-a and its signaling pathway as
early mediators in the inflammatory cascade, it makes sense
that cytokines from the TNF-family have a protagonical role in
the genesis of PVR. Our finding in the TNF locus reinforces this
notion.
Apoptosis may be another important mechanism in PVR,
where TGF-b has been strongly implicated.46 Amongst other
numerous biological functions of TGF-b, of significance may be
the stimulation of epithelial-mesenchymal cells, fibroblast-
myofibroblast conversion, and the enhanced expression of
extracellular matrix proteins47; all key processes in the
establishment of PVR. The TGF-b family members (TGFb1–3)
bind to their membrane receptors, and use the SMADs
signaling pathway. SMAD2 and 3 (known as receptor-regulated
SMADs) play an important role in the activation of TGF-b–
dependent gene targets, with SMAD3 mediating the mainly
profibrotic actions of TGF-b. SMAD7 is known to be inhibitory,
blocking phosphorylation of SMAD2/3.47,48 These events are
evidence of potentially important roles that SMAD proteins
could have in the pathogenesis of PVR. In fact, over expression
of SMAD7 suppresses the fibrotic response of RPE cells to TGF-
b2 in mice, inhibiting the RPE cells transition to myofibro-
blasts.49 Our results highlight the possible role of SMAD7 in
the development of PVR in humans.
One question that arises from the above is why TGF-b was
not significantly associated to the disease. One explanation
could be that there were three markers (two in the TGF-b1 and
one in the TGF-b2) without information either for failure in the
design pipeline or during the genotyping process. That means
that some regions of the gene were not exhaustively studied as
there were some SNPs that could not be genotyped. In order to
solve this problem, TGF-b should be studied by other method.
In summary, we have confirmed that two genes previously
implicated in the establishment of PVR are indeed significantly
associated to the disease in Europeans undergoing retinal
detachment surgery. These results may help us to understand
the molecular basis of this complication and could potentially
guide us to develop new strategies in the prevention or
treatment of PVR. Further experimental studies on these genes
are now warranted.
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